scholarly journals MOJ Drug Design Development & Therapy

2018 ◽  
Keyword(s):  
Drug Design ◽  
Design Development ◽  
Development Therapy

Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor

1988 ◽  
Vol 31 (6) ◽  
pp. 1087-1093 ◽  
Author(s):  
Marcel F. Hibert ◽  
Maurice W. Gittos ◽  
Derek N. Middlemiss ◽  
Anis K. Mir ◽  
John R. Fozard
Keyword(s):  
Drug Design ◽  
Design Development ◽  
Predictive Tool ◽  
Receptor Mapping ◽  
Computer Aided

Quercetin derivatives: Drug design, development, and biological activities, a review

2021 ◽  
pp. 114068
Author(s):  
Seyedeh Roya Alizadeh ◽  
Mohammad Ali Ebrahimzadeh
Keyword(s):  
Drug Design ◽  
Biological Activities ◽  
Design Development ◽  
Quercetin Derivatives

Drug Design, Development and Therapy

2017 ◽  
Author(s):  
Erzsébet Tóth-Czifra
Keyword(s):  
Drug Design ◽  
Design Development

scholarly journals Drug Design, Development and Therapy

10.2147/dddt ◽  
2020 ◽  
Keyword(s):  
Drug Design ◽  
Design Development

scholarly journals Anticancer Drug Design: Development of Cyclin-Dependent Kinase Inhibitors Using In Silico Techniques

2020 ◽  
Author(s):  
Derouicha Matmour ◽  
Nawel Achachi ◽  
Yassine Mérad ◽  
Houari Toumi
Keyword(s):  
Cell Cycle ◽  
Drug Design ◽  
Anticancer Drug ◽  
Mammalian Cells ◽  
Drug Candidate ◽  
Biological Databases ◽  
Design Development ◽  
Qsar Study ◽  
Structure Based Drug Design ◽  
Restriction Point

In mammalian cells, proliferation is controlled by the cell cycle, where cyclin-dependent kinases regulate critical checkpoints. CDK4 is considered a highly validated anticancer drug target due to its essential role in regulating cell cycle progression at the G1 restriction point. Our objective is to design novel CDK4 inhibitors using Structure-Based Drug Design and Quantitative Structure-Activity Relationship techniques. We used bioinformatics tools and biological databases. QSAR study of CDK4 inhibitors has given us an idea of the physicochemical features of studied compounds and their correlation with the IC50 activity. The docking study has helped to highlight the molecule key elements to refine in order to get a more potent compound of CDK4.The Molecule under the code 21366124 which has the low IC50= 3 nmole shows the most binding affinity with a score value of ΔG=-9,8 kcal/mol. As prospects, it would be very interesting to synthesize this drug candidate and to test its inhibitory activity on cell culture of breast cancer.

scholarly journals A Review on Recent Rational Approaches to Drug Design, Development and Its Discovery

2020 ◽  
Vol 10 (4) ◽  
Author(s):  
Bisht Dheeraj ◽  
Kamal Kant Arya Rajeshwar ◽  
Raj Pal Govind ◽  
Pratap Singh Ravindra
Keyword(s):  
Drug Design ◽  
Design Development
Sign in / Sign up

Export Citation Format

Share Document